Immuneering Corporation (IMRX)
2.01
0.06 (3.08%)
At close: Jan 15, 2025, 11:46 AM
Company Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates.
Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors.
The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs.
Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Immuneering Corporation
| Country | United States |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 66 |
| CEO | Dr. Benjamin J. Zeskind M.B.A., Ph.D. |
Contact Details
Address: 245 Main Street Cambridge, Massachusetts United States | |
| Website | https://immuneering.com |
Stock Details
| Ticker Symbol | IMRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001790340 |
| CUSIP Number | 45254E107 |
| ISIN Number | US45254E1073 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Benjamin J. Zeskind M.B.A., Ph.D. | Co-Founder, President, Chief Executive Officer & Director |
| Leah R. Neufeld | Chief People Officer |
| Michael D. Bookman J.D. | Chief Legal Officer & Secretary |
| Dr. Brett M. Hall Ph.D. | Chief Scientific Officer |
| Dr. Peter King Ph.D. | Head of Discovery & Vice President |
| Dr. Praveen Nair Ph.D. | Head of Translational Pharmacology & Vice President |
| Harold E. Brakewood | Chief Business Officer |
| Mallory Morales CPA | Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer |
| Paula George CPA | Director of Accounting & Operations and Assistant Corporate Controller |
| Robert J. Carpenter M.B.A., M.S. | Co-Founder & Chair Emeritus |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 8-K | Current Report |
| Jan 07, 2025 | 8-K | Current Report |
| Jan 02, 2025 | 4 | Filing |
| Jan 02, 2025 | 4 | Filing |
| Jan 02, 2025 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Oct 02, 2024 | 8-K/A | [Amend] Current Report |